Enhancement of MDM2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells
出版年份 2022 全文链接
标题
Enhancement of MDM2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells
作者
关键词
-
出版物
Cancer Genetics
Volume 266-267, Issue -, Pages 57-68
出版商
Elsevier BV
发表日期
2022-06-12
DOI
10.1016/j.cancergen.2022.06.003
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- MDM2 inhibition: an important step forward in cancer therapy
- (2020) Marina Konopleva et al. LEUKEMIA
- Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway
- (2020) Yingying Cui et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21WAF1/CIP1 and p27KIP1 in Cancer Cells
- (2019) Umamaheswari Natarajan et al. Medicina-Lithuania
- Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells
- (2018) Umamaheswari Natarajan et al. Cells
- Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1
- (2017) A Cosson et al. LEUKEMIA
- Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
- (2017) Maryam Zanjirband et al. Oncotarget
- Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia
- (2016) Thomas B. Alexander et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
- (2016) Albiruni R. Abdul Razak et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma
- (2016) Mrinal M. Gounder et al. JOURNAL OF CLINICAL ONCOLOGY
- Chromosome region maintenance 1 expression and its association with clinical pathological features in primary carcinoma of the liver
- (2016) QIAO-LING XIE et al. Experimental and Therapeutic Medicine
- Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma
- (2016) Manoj Garg et al. Oncotarget
- Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia
- (2015) Z. A. Hing et al. BLOOD
- Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program
- (2015) Edward F. Attiyeh et al. PEDIATRIC BLOOD & CANCER
- Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein
- (2015) Jo Ishizawa et al. PHARMACOLOGY & THERAPEUTICS
- KPT-330 has antitumour activity against non-small cell lung cancer
- (2014) H Sun et al. BRITISH JOURNAL OF CANCER
- Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy
- (2014) Min Lu et al. FEBS LETTERS
- Nucleo-cytoplasmic transport as a therapeutic target of cancer
- (2014) Giovanni Luca Gravina et al. Journal of Hematology & Oncology
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- Antitumor Effects of a Novel Chromosome Region Maintenance 1 (CRM1) Inhibitor on Non-Small Cell Lung Cancer Cells In Vitro and in Mouse Tumor Xenografts
- (2014) Shuai Wang et al. PLoS One
- Prognostic impact and targeting of CRM1 in acute myeloid leukemia
- (2013) K. Kojima et al. BLOOD
- KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia
- (2013) Julia Etchin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276
- (2013) J Schmidt et al. LEUKEMIA
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
- (2013) Y-T Tai et al. LEUKEMIA
- CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas
- (2013) Fang Zhou et al. MEDICAL ONCOLOGY
- p53 SUMOylation promotes its nuclear export by facilitating its release from the nuclear export receptor CRM1
- (2013) Aleixo Santiago et al. MOLECULAR BIOLOGY OF THE CELL
- Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1
- (2013) Qingxiang Sun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Characterization of BRCA1 Protein Targeting, Dynamics, and Function at the Centrosome
- (2012) Kirsty M. Brodie et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- NESdb: a database of NES-containing CRM1 cargoes
- (2012) Darui Xu et al. MOLECULAR BIOLOGY OF THE CELL
- Nuclear export of proteins and drug resistance in cancer
- (2011) Joel G. Turner et al. BIOCHEMICAL PHARMACOLOGY
- CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity
- (2011) K. Sakakibara et al. BLOOD
- Protein and its function based on a subcellular localization
- (2011) Jana Ćmielová et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition
- (2009) J. G. Turner et al. CANCER RESEARCH
- Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo
- (2009) S. C. Mutka et al. CANCER RESEARCH
- Dysregulation of apoptosis in hepatocellular carcinoma cells
- (2009) Isabel Fabregat WORLD JOURNAL OF GASTROENTEROLOGY
- Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer
- (2008) Aurelia Noske et al. CANCER
- The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation
- (2008) Pauline J. van der Watt et al. INTERNATIONAL JOURNAL OF CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started